



American Association for Cancer Research

FINDING CURES TOGETHERSM

For media inquiries or trouble shooting, please contact Rachel Salis-Silverman, rachel.silverman@aacr.org or 215-446-7159. Visit our [newsroom](#).

AACR Video News Release: Lower Thirds and Script

Lower Thirds

Philip Prichard; Memphis, Tennessee; Kidney Cancer

Nancy E. Davidson, MD; AACR President 2016-2017; Director, University of Pittsburgh Cancer Institute

Script

When Philip Prichard's kidney cancer returned, he turned to a clinical trial of a checkpoint inhibitor – a type of cancer immunotherapy that had already been approved for patients with melanoma and lung cancer.

Within weeks of his first infusion, Philip's kidney cancer began to respond to the drug.

Philip: "It basically takes your immune system and turns it on to fight the cancer. My quality of my life improved monthly."

His story is featured in a new report from the American Association for Cancer Research.

The *AACR Cancer Progress Report 2016* shows that four of the 13 new anti-cancer therapeutics approved in the last 12 months are immunotherapeutics.

Immunotherapy harnesses a patient's own immune system to destroy cancer cells. For many patients with different forms of the disease, these cutting-edge treatments are proving to be lifesaving.

Dr. Davidson: "It is impressive to see the number of new therapies that have come available to patients. This is a direct result of the research we've been able to support over the last several decades."

Philip: "It's wonderful that we've come this far and that we're able to have a drug ... that can use your own system to fight off cancer."

Thanks to advances in immunotherapy, precision medicine and other treatment strategies, today there are 15.5 million cancer survivors living in the United States.

For more information, go to CancerProgressReport.org.

#

Follow us: *Cancer Research Catalyst* <http://blog.aacr.org>; Twitter [@AACR](https://twitter.com/AACR); and Facebook <http://www.facebook.com/aacr.org>

For AACR information, visit [Fast Facts](#).

About the American Association for Cancer Research

Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 37,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 108 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with nearly 19,500 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.